Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Metrion Biosciences’ CEO Dr Andrew Southan presents an overview of Metrion Biosciences, highlighting the company’s vision, expertise and services. December 10th, 2020.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.